Analysts forecast that Caladrius Biosciences Inc (NASDAQ:CLBS) will report ($0.44) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Caladrius Biosciences’ earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.44). Caladrius Biosciences reported earnings per share of ($0.42) during the same quarter last year, which suggests a negative year-over-year growth rate of 4.8%. The firm is scheduled to report its next quarterly earnings results on Thursday, August 8th.
On average, analysts expect that Caladrius Biosciences will report full year earnings of ($1.51) per share for the current financial year, with EPS estimates ranging from ($1.88) to ($0.91). For the next financial year, analysts forecast that the firm will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.90) to ($0.54). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Caladrius Biosciences.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.05).
CLBS has been the topic of a number of recent research reports. Chardan Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Caladrius Biosciences in a report on Sunday, May 12th. Zacks Investment Research upgraded shares of Hallmark Financial Services from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, WBB Securities started coverage on shares of Caladrius Biosciences in a report on Tuesday, May 14th. They set a “speculative buy” rating and a $6.75 target price on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $8.63.
Shares of NASDAQ CLBS traded up $0.09 during midday trading on Friday, reaching $2.89. The company’s stock had a trading volume of 85,663 shares, compared to its average volume of 60,063. Caladrius Biosciences has a fifty-two week low of $2.16 and a fifty-two week high of $6.83. The stock has a 50 day simple moving average of $2.68.
An institutional investor recently bought a new position in Caladrius Biosciences stock. Wesbanco Bank Inc. purchased a new position in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $36,000. Wesbanco Bank Inc. owned approximately 0.10% of Caladrius Biosciences as of its most recent filing with the SEC. 7.59% of the stock is currently owned by institutional investors.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Further Reading: How to track put option volume
Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.